Market Overview

UPDATE: Piper Jaffray Initiates Oncothyreon at Underweight on Pipeline Risk

Related ONTY
Oncothyreon And Celldex Therapeutics Announce Initiation Of Combination Immunotherapy Clinical Trial Of ONT-10 and Varlilumab
UPDATE: H.C. Wainwright & Co. Initiates Coverage On Oncothyreon On Significant Upside

Piper Jaffray initiated coverage on Oncothyreon (NASDAQ: ONTY) with an Underweight rating and a $1.00 price target.

Piper Jaffray commented, "Following Stimuvax's implosion, PI3K-inhibitor PX-866 remains as the lead candidate. While PX-866 has limited intriguing but early data, we see meaningful levels of programmatic risk given its legacy, mechanism, and well-heeled competition in the PI3K space. We view PX-866's pan-PI3K activity and irreversibility as possibly having efficacy and safety implications. Proof of concept PIIa studies should read out this year in colon & lung (early 2Q), brain & prostate (end 2Q), and head/neck (late 2H), all of which we expect to “require interpretation”.

Oncothyreon closed at $2.27 on Thursday.

Latest Ratings for ONTY

DateFirmActionFromTo
Oct 2014Wainwright Initiates Coverage onBuy
Mar 2014Canaccord GenuityDowngradesBuyHold
Mar 2014Stifel NicolausMaintainsBuy

View More Analyst Ratings for ONTY
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (ONTY)

Around the Web, We're Loving...

Get Benzinga's Newsletters